Experimental MDS combo trial halted early – what we know
NCT ID NCT04878432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested adding sabatolimab, an experimental immunotherapy, to standard chemotherapy drugs (azacitidine, decitabine, or oral decitabine) in 39 adults with intermediate to very high risk myelodysplastic syndrome (MDS). The main goal was to check safety, and the trial also looked at how many patients achieved complete remission within 12 months. The study was terminated early, so the full picture is limited, but the data collected helps understand the combination's safety and potential effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sabatolimab (MBG453) plus a hypomethylating agent (azacitidine, decitabine, or oral decitabine/cedazuridine)
What this could lead to
If successful, this combination could offer a new treatment option for people with higher-risk myelodysplastic syndrome (MDS) by improving remission rates.
What could go wrong
The trial was terminated early with only 39 participants, so results are limited. It is unclear if sabatolimab adds meaningful benefit over standard therapy, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME(MDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32803, United States
-
Arizona Oncology Associates
Tucson, Arizona, 85745, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mount Sinai Medical Center
New York, New York, 10029-6574, United States
-
SCRI-Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Texas Oncology San Antonio USO
San Antonio, Texas, 78240, United States
-
Tisch Hospital NYU Langone
New York, New York, 10016, United States
-
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
Uni of Massachusetts Medical Center
Worcester, Massachusetts, 01655, United States
-
University Hospitals Of Cleveland
Cleveland, Ohio, 44106, United States
-
University Of Michigan
Ann Arbor, Michigan, 48109, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06520, United States